Glioblastoma (GBM) contains a dense collagen-IV-rich extracellular matrix (ECM) that restricts intratumoral transport of therapeutic agents. To overcome this barrier, we engineered protease-responsive, collagenase-functionalized theranostic nanoparticles (TNP-collagenase) by conjugating collagenase-IV to the FDA-approved iron oxide nanoparticle ferumoxytol through a cathepsin B-cleavable linker, enabling tumor-specific enzyme activation. TNP-collagenase retained high MRI relaxivity and exhibited minimal cytotoxicity. In 3D tumor spheroids, TNP-collagenase significantly enhanced nanoparticle penetration compared with ferumoxytol alone. In an orthotopic U87MG mouse model, MRI demonstrated greater tumor accumulation of TNP-collagenase, reflected by significantly reduced tumor T2 relaxation times. TNP-collagenase combined with temozolomide (TMZ) induced significant tumor regression compared with PBS + TMZ and ferumoxytol + TMZ. Histological analyses confirmed degradation of perivascular collagen-IV and improved intratumoral distribution of therapeutics. These results establish enzyme-activated ECM remodeling as a nanomedicine strategy to enhance drug delivery and therapeutic efficacy in GBM while enabling noninvasive imaging of treatment response.

Therapeutic cancer vaccines have historically faced limited clinical efficacy, with Sipuleucel-T being the only FDA-approved option until recently. However, personalized mRNA vaccines—notably Moderna's mRNA-4157 and BioNTech's autogene cevumeran—have demonstrated substantial improvements in recurrence reduction and survival outcomes, revitalizing the field. These vaccines leverage patient-specific tumor antigens to generate targeted immune responses. The review examines multiple vaccine platforms including DNA-, mRNA-, peptide-, dendritic cell-, and whole-cell-based approaches, while addressing challenges such as tumor heterogeneity and immunosuppressive microenvironments. Advanced delivery systems utilizing lipid-polymer hybrids, biomimetic membranes, and stimulus-responsive nanovaccines enhance lymph node targeting and dendritic cell activation. Integration with artificial intelligence for antigen selection and multiomics for patient stratification optimizes vaccine design precision. Combination therapies with immune checkpoint inhibitors further enhance efficacy. Clinical evidence, particularly in melanoma and pancreatic cancer, demonstrates these strategies' potential for durable antitumor immunity and long-term protection, marking a significant shift toward precision cancer immunotherapy.

Renal cell carcinoma remains a significant clinical challenge despite the success of immune checkpoint inhibitors, as primary and acquired resistance, patient heterogeneity, and systemic toxicity continue to limit treatment effectiveness. The disease employs three interconnected immune evasion mechanisms: defective immune priming combined with checkpoint-mediated immunosuppression, vascular-metabolic barriers that prevent immune cell infiltration and function, and a suppressive tumor microenvironment orchestrated by myeloid cells, regulatory lymphocytes, cytokines, and extracellular vesicles. These multilayered barriers collectively impair effector cell function and drive T-cell exhaustion. This comprehensive review published in the International Journal of Nanomedicine examines how nanodelivery platforms can overcome these immunosuppressive constraints through programmable payload delivery, spatiotemporally controlled local release, and material-mediated tumor microenvironment modulation. The authors systematically discuss intervention strategies targeting antigen presentation restoration, innate immune sensing activation, effector cell maintenance, vascular-metabolic remodeling, and suppressive immune network reprogramming. The review compares lipid-based, polymeric, and inorganic nanoplatforms, providing crucial insights for developing next-generation combination therapies to enhance RCC treatment outcomes.

Researchers have developed an innovative engineered macrophage therapy called signal-switching receptor CAR-macrophages (SR CAR-Ms) to overcome the immunosuppressive barriers that limit conventional CAR-T cell therapy in solid tumors. These macrophages are engineered to recognize interleukin-10 (IL-10), a major immunosuppressive cytokine abundant in solid tumors, and convert this inhibitory signal into pro-inflammatory activation through Toll-like receptor 9 (TLR9) signaling. In preclinical studies using an orthotopic 4T1 breast cancer model, SR CAR-Ms selectively accumulated in tumors, depleted local IL-10, induced inflammatory cytokine production, suppressed tumor growth, and prolonged survival without systemic toxicity. The engineered macrophages adopted an M1-like phenotype with enhanced phagocytic capacity and promoted dendritic cell maturation while preventing T cell exhaustion. Further advancement was achieved by creating dual-function SRPα CAR-Ms that also secreted anti-PD-L1 antibodies, outperforming monotherapies alone. This signal-switching paradigm transforms an immunosuppressive cytokine into a location-specific activation trigger, offering a promising new strategy for treating solid malignancies resistant to conventional immunotherapies.

Cancer stem cells (CSCs) drive tumor metastasis, recurrence, and drug resistance by maintaining stemness through redox homeostasis, metabolic plasticity, and specialized microenvironmental niches. This comprehensive review examines stimuli-responsive nanomaterials designed to modulate CSCs for improved therapeutic outcomes. Rather than employing conventional cytotoxic approaches that eliminate non-CSCs while allowing CSCs to survive and regenerate tumors, the field is shifting toward fate regulation strategies that reprogram cellular behavior and disrupt stemness-related networks. The review details the rational design of smart nanoplatforms responsive to both endogenous tumor microenvironment triggers and exogenous physical fields, explaining how these synergized platforms precisely modulate cellular behaviors. Key translational challenges are identified, including the need for real-time CSC monitoring and development of biomimetic organoid models to intercept intercellular communications. The work provides a structural roadmap for developing next-generation multimodal nanotechnologies to achieve efficient CSC modulation and anti-tumor treatment, representing a significant paradigm shift from simple elimination to sophisticated cellular reprogramming strategies.

Natural killer cells possess inherent capacity to eliminate transformed cells without prior sensitization, yet their therapeutic effectiveness against solid tumors remains limited. This paradox stems from complex inhibitory pathways centered on killer cell immunoglobulin-like receptors and the CD94/NKG2A axis, which regulate NK-cell tolerance and function. Tumors evade immune surveillance by dynamically remodeling HLA-I expression, preserving non-classical HLA-E to sustain inhibitory signaling. The tumor microenvironment further suppresses NK-cell activity through stromal barriers, hypoxia, metabolic stress, and immunosuppressive networks that impair infiltration and cytotoxicity. Consequently, therapeutic blockade of KIR or NKG2A alone has produced only modest clinical benefits in solid tumors despite strong biological rationale. This analysis, conducted by researchers at Italian institutions including the University of Genoa and University of Udine, positions the KIR and CD94/NKG2A network as both therapeutic target and framework for next-generation NK-cell immunotherapies. Future approaches will likely integrate checkpoint modulation with donor- and patient-tailored NK-cell selection, engineered NK-cell products with enhanced metabolic resilience, and tumor microenvironment remodeling strategies to overcome multilayered immune suppression.

CAR-T cell therapy has achieved remarkable success in hematological malignancies, but its activity in solid tumors remains constrained by multiple interrelated barriers. The scarcity of truly tumor-specific antigens, together with heterogeneous or low-density target expression and antigen loss, can impair tumor recognition and promote immune escape. Even when target antigens are present, CAR-T cells often fail to reach and penetrate tumor lesions because of chemokine–receptor mismatch, abnormal tumor vasculature, and extracellular matrix-rich stromal barriers. Within the tumor bed, checkpoint signaling, suppressive cytokines and immune cells, and metabolic stress further limit CAR-T cell expansion, persistence, and cytotoxic function. These linked obstacles suggest that improving therapeutic outcomes in solid tumors requires more than enhancing CAR-T-cell killing capacity alone.

The effectiveness of cancer immunotherapy may depend not only on which immune cells reach a tumor, but also on when they arrive. Researchers from Sungkyunkwan University and Seoul National University College of Medicine have demonstrated that the sequence of interactions between immune cells and glioblastoma cells can significantly influence treatment response. Their findings, published in Neuro-Oncology, suggest that timing is an overlooked factor in the tumor microenvironment and could become an important consideration in the development of personalized immunotherapies for one of the deadliest forms of brain cancer.

Nucleic acid-based therapeutic molecules including small interfering RNA (siRNA), microRNA(miRNA), antisense oligonucleotides (ASOs), messenger RNA (mRNA), and DNA-based gene therapy have tremendous potential for treating diseases in the central nervous system (CNS). However, achieving clinically meaningful delivery to the brain and particularly to target cells and sub-cellular compartments is typically very challenging. Mediating cell-specific delivery in the CNS would be a crucial advance that mitigates off-target effects and toxicities. In this review, we describe these challenges and provide contemporary evidence of advances in cellular and sub-cellular delivery using a variety of delivery mechanisms and alternative routes of administration, including the nose-to-brain approach. Strategies to achieve subcellular localization, endosomal escape, cytosolic bioavailability, and nuclear transfer are also discussed. Ultimately, there are still many challenges to translating these experimental strategies into effective and clinically viable approaches for treating patients.

Researchers from German institutions including the German Cancer Research Center and Mannheim University Medical Center have published encouraging long-term results from a clinical trial testing a novel peptide vaccine against gliomas, the most common malignant brain tumors. The vaccine targets a specific genetic mutation in the IDH1 enzyme that drives tumor growth and appears in the majority of these cancers. This mutation creates a neoepitope—a foreign protein structure that the immune system can recognize. In the Phase 1 NOA 16 trial involving 33 patients with high-grade astrocytomas, participants received the vaccine alongside standard treatment comprising surgery, radiation, and chemotherapy. After up to eight years of follow-up, 66 percent of patients remained alive and 42 percent showed no disease progression, significantly exceeding historical median survival times of 2.5 to 5 years. Patients with completely resected tumors demonstrated even higher survival rates. These results suggest the IDH1-targeted vaccine could fundamentally transform glioma treatment outcomes, offering new hope for patients with this previously difficult-to-treat cancer.

# Summary A comprehensive review published in Frontiers in Oncology by Wu, Liu, Lv, Ming, Song, and Chu examines lipid metabolic plasticity in glioblastoma, the most aggressive form of brain cancer. The study investigates how glioblastoma cells reprogram their lipid metabolism to survive and resist therapeutic interventions. The research explores the mechanisms underlying metabolic plasticity, demonstrating how tumor cells dynamically switch between different metabolic states to adapt to changing microenvironmental conditions. The authors analyze how these metabolic adaptations reshape the tumor microenvironment, affecting immune cell infiltration and creating immunosuppressive conditions. The review identifies lipid metabolism reprogramming as a critical driver of therapeutic resistance in glioblastoma, presenting significant obstacles to current treatment strategies. By elucidating these metabolic mechanisms and their relationship to tumor microenvironment remodeling, the study highlights novel therapeutic opportunities targeting lipid metabolism as a promising approach to overcome resistance and improve clinical outcomes for glioblastoma patients. This work advances understanding of how metabolic flexibility contributes to glioblastoma's aggressive phenotype and treatment evasion.

FDA-approved oncolytic herpes simplex virus-1 (oHSV) represents a promising viro-immunotherapy for solid tumors, yet its clinical efficacy is often limited by tumor adaptations including immune suppression and enhanced aggressiveness. Researchers investigating the molecular mechanisms of oHSV resistance discovered that the therapy activates insulin-like growth factor 1 receptor (IGF1R) signaling, promoting tumor proliferation and therapeutic resistance. The study evaluated combining IGF1R blockade with oHSV and radiotherapy (RTx) across breast cancer and glioblastoma models. While IGF1R inhibition alone showed limited benefit, combining it with oHSV produced modest but significant cytotoxic improvements in both in vitro and xenograft models. Notably, dual oHSV and RTx co-treatment activated both IGF1R and YAP1 signaling pathways in resistant cells, identifying the IGF1R/YAP1 axis as a critical resistance mechanism. The triple combination of oHSV, RTx, and IGF1R blockade achieved synergistic anti-tumor effects, suppressed YAP1 expression, and significantly enhanced survival in orthotopic tumor models. These findings establish the IGF1R/YAP1 axis as a key resistance driver and provide compelling rationale for clinical development of this triple-combination strategy to improve outcomes in breast cancer and glioblastoma patients.

This research by Egiroh Omene examines metabolic competition within the glioblastoma tumor microenvironment and its role in immune exclusion. The study investigates how glucose, glutamine, and lactate metabolism shape immune cell function and tumor-associated macrophage activity in glioblastoma, an aggressive brain cancer with notoriously poor immunotherapy responses. The analysis reveals that cancer cells compete with immune cells for critical metabolic substrates, creating a nutrient-depleted microenvironment that suppresses anti-tumor immunity. Specifically, the research identifies glucose glycolysis, glutamine metabolism, and lactate accumulation as key mechanisms driving immune cell dysfunction and exclusion from tumors. The findings highlight metabolic reprogramming as a promising therapeutic strategy to restore immune function. By targeting these metabolic pathways through pharmacological interventions, researchers propose reversing immune suppression and enhancing immunotherapy efficacy. This work addresses a fundamental barrier to glioblastoma treatment, suggesting that combining metabolic modulation with conventional immunotherapies could improve patient outcomes by reshaping the hostile tumor microenvironment to support immune activation.

Researchers conducted a Phase 1 clinical trial investigating personalized multivalent neoantigen DNA vaccination as an adjuvant treatment for glioblastoma, an aggressive brain cancer. Following initial surgical resection, patients received the personalized neoantigen vaccine designed to stimulate immune responses against tumor-specific mutations. The trial evaluated immunogenicity, progression-free survival, and overall survival while monitoring for dose-limiting toxicity and serious adverse events, including fatal infections. Results demonstrated that the DNA vaccination approach induced activation of peripheral T cells and generated robust immune responses. The study identified long-term survivors among participants and showed clinical activity of the personalized therapeutic vaccine in combination with standard glioblastoma treatment. This research is significant because it explores personalized immunotherapy tailored to individual tumor mutations, potentially offering a more targeted approach to treating one of the most lethal cancers. The findings support further investigation into neoantigen-based DNA immunization as an adjuvant strategy to improve outcomes in glioblastoma patients and validate the broader potential of personalized cancer vaccines in oncology.

Researchers at the University of Virginia Comprehensive Cancer Center have developed an innovative therapeutic approach to treat glioblastoma, the most aggressive and deadliest form of brain cancer. Led by Dr. Roger Abounader, the team identified microRNAs capable of simultaneously suppressing multiple malfunctioning genes that drive glioblastoma formation and progression. The breakthrough uses a combination of brain-penetrating nanoparticles, focused ultrasound waves, and microbubbles to deliver these microRNAs across the blood-brain barrier, a natural protective mechanism that typically prevents anticancer drugs from reaching brain tumors. Published in the Journal of Clinical Investigation, this approach addresses a critical challenge in glioblastoma treatment: the inability to target multiple cancer-promoting molecules simultaneously due to drug toxicity concerns. With glioblastoma claiming over 13,000 American lives annually and currently treated through surgery, radiation, and chemotherapy with limited success, this microRNA-based strategy offers potential for more effective therapies. Abounader's team aims to advance these findings toward clinical trials, potentially transforming treatment options for glioblastoma and other brain tumors.

Glioblastoma (GBM) remains one of the most aggressive brain cancers, with approximately 3-5 cases per 100,000 people diagnosed annually. In Germany, over 7,000 malignant central nervous system tumors were recorded in 2022, with glioblastoma incidence ranging from 1.6 to 4.3 per 100,000 depending on demographics. Despite its relatively low incidence, GBM carries a devastating prognosis, with median overall survival under current standard care—surgery, radiation, and chemotherapy—remaining between 10-15 months and five-year survival rates below 10 percent. A large German retrospective study of over 40,000 cases from 1999-2014 confirmed median overall survival of 10.0 months, though modest improvements in two-year survival rates were noted over time. In response to these poor outcomes, immuno-oncology emerges as a promising therapeutic approach. This strategy leverages the patient's immune system to selectively target cancer cells while preserving healthy tissue by training immune cells to distinguish malignant from normal tissue. Unlike conventional treatments, immunotherapy offers potential to improve survival outcomes and prevent relapse in primary brain tumors, making it particularly appealing for GBM patients seeking advanced treatment options.

Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor in adults accounting for 15% of cases, carries a dismal prognosis with a median survival of 14.6 months and a 5-year survival rate of only 3.3%, despite standard treatments including surgical resection, ionizing radiation, and temozolomide. The Cancer Genome Atlas characterized distinct GBM transcriptional subtypes and identified an epigenetic subtype (G-CIMP) associated with IDH1 mutations. Although recurrent mutations in EGF receptor and PDGF receptor A have been discovered, neither has proven therapeutically promising. The article explores therapeutic targeting of tumor-associated macrophages as a potential approach to overcome current treatment limitations. Key challenges include the blood-brain barrier's impermeability to most pharmaceutical agents and GBM's substantial intratumoral heterogeneity, which may prevent single-agent efficacy. Understanding and targeting the immunological microenvironment, particularly macrophage involvement, represents a critical avenue for developing more effective therapeutic strategies against this devastating disease.

Recent discoveries of meningeal lymphatic vessels (MLVs) have fundamentally transformed understanding of immune regulation in the central nervous system, challenging the traditional view of the brain as an immune-privileged organ. This comprehensive review examines the critical intersection between MLVs and glioblastoma (GBM), the most aggressive primary brain tumor classified as WHO grade 4. Despite advances in neurosurgical techniques and adjuvant therapies, GBM remains therapeutically challenging, with a median overall survival of only 14.6 months, primarily due to its highly immunosuppressive microenvironment and resistance to conventional and immunotherapy approaches. The emerging evidence indicates that MLVs play pivotal roles in CNS immune surveillance, cerebrospinal fluid drainage, and solute clearance—all directly connected to GBM pathophysiology. This review systematically analyzes bidirectional interactions between MLVs and GBM, particularly regarding antigen transport, T cell activation, and tumor dissemination. The authors evaluate promising therapeutic strategies targeting MLVs through lymphangiogenic stimulation and alternative immune modulation routes, including novel drug delivery pathways. These approaches represent innovative opportunities to enhance anti-tumor immunity and potentially establish next-generation treatment paradigms for GBM management.

Researchers have developed an engineered oncolytic virus designed to overcome resistance to immunotherapy in cancer treatment. The virus coexpresses a PD-L1 inhibitor alongside GM-CSF, enabling it to secrete the inhibitor systemically to block PD-L1 expression on both tumor and immune cells. When administered via intratumoral injection, this approach successfully neutralizes PD-L1-mediated immunosuppression during both the priming and effector phases of immune response, activating tumor neoantigen-specific T cell responses against mutations. The treatment effectively rejected both directly injected tumors and distant metastases in the study. This innovation addresses a critical clinical problem: while tumor neoantigens derived from mutations can theoretically trigger immune responses, the immunosuppressive tumor microenvironment typically blocks these responses through checkpoint molecules like PD-L1. Although PD-1/PD-L1 blockade has demonstrated efficacy in certain cancers including melanoma and lung carcinoma, the majority of cancer patients remain resistant to these therapies. This engineered oncolytic virus represents a promising individualized therapeutic option, particularly for patients who have failed conventional checkpoint inhibitor treatment, by combining viral-mediated tumor destruction with enhanced neoantigen-specific immunity.

Researchers from Chinese medical institutions conducted a comprehensive review examining how inflammation functions as a central regulator of immunotherapy efficacy in head and neck squamous cell carcinoma (HNSCC). The study analyzed the complex interplay between chronic inflammatory signals, immune cell behavior, and tumor biology to explain immunotherapy response variability. Key findings revealed that inflammatory pressure reprograms critical immune cells—including macrophages, regulatory T cells, exhausted CD8+ T cells, and dendritic cell subsets—transforming them from tumor-suppressing sentinels into promoters of tumor growth and invasion. The researchers identified inflammation-driven signaling pathways including NF-κB/STAT3, IL-6/TNFα, TGF-β, and PI3K-4EBP1-SOX2 as orchestrators of immunotherapy response. They catalogued biomarkers such as PD-L1, CD163/CD68 ratios, LAMP3, and CD44 isoforms that provide enhanced patient stratification when analyzed at single-cell and spatial resolution. This framework is significant because it demonstrates how understanding inflammation-induced immune cell plasticity and associated molecular pathways enables better prediction of checkpoint blockade success or failure, potentially improving treatment outcomes for HNSCC patients.